Christine Klaskin - Jun 11, 2024 Form 4 Insider Report for AGENUS INC (AGEN)

Role
PFO & PAO
Signature
/s/Christine Klaskin
Stock symbol
AGEN
Transactions as of
Jun 11, 2024
Transactions value $
$0
Form type
4
Date filed
6/18/2024, 04:05 PM
Previous filing
Jan 9, 2023
Next filing
Nov 18, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGEN Stock Option Award $0 +10.6K $0.00 10.6K Jun 11, 2024 Common Stock 10.6K $12.26 Direct F1
transaction AGEN Stock Option Award $0 +6.25K $0.00 6.25K Jun 11, 2024 Common Stock 6.25K $12.26 Direct F2
transaction AGEN Stock Option Award $0 +3.13K $0.00 3.13K Jun 11, 2024 Common Stock 750 $13.25 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options were granted on January 16, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. These options vest as to 50% of the underlying shares on June 27, 2024 and 50% of the underlying shares on September 27, 2024. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 212,840 Stock Options with an exercise price of $0.61.
F2 Options were granted on January 16, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on January 16, 2025 and the balance vesting in equal quarterly installments thereafter. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 125,000 Stock Options with an exercise price of $0.61.
F3 Options were granted on January 26, 2024 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting on June 11, 2024. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on January 26, 2025 and the balance vesting in equal quarterly installments thereafter. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 62,500 Stock Options with an exercise price of $0.66.